Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ITI-1771
- Development stage
- Preclinical
- Lead developer
- Immunomic Therapeutics
- Modality
- mRNA Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules
- Administration
- Intramuscular
01
Overview
ITI-1771 is a therapeutic vaccine in preclinical development by Immunomic Therapeutics. It is designed to treat cancers driven by the expression of cytomegalovirus (CMV), with potential indications including colorectal cancer, glioblastoma (GBM), and triple negative breast cancer. The vaccine utilizes a self-amplifying RNA (saRNA) platform to stimulate an immune response against CMV-expressing tumor cells[1][2][3].
Beyond the preview
Go deeper on ITI-1771.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ITI-1771.